JNJ-2113 – Talk Bio

Actionable Insights Powered by AI

J&J’s Oral IL-23 Drug Icotrokinra Surpasses Sotyktu in Phase 3 Psoriasis Trials

1 month ago talkbio0Tagged Dental Plaque, deucravacitinib, IL-23 receptor antagonist, JNJ-2113, Johnson & Johnson, Myers, oral peptide, Phase 3 clinical trial, Psoriasis, skin clearance, Sotyktu

Icotrokinra; JNJ-2113; Johnson & Johnson; IL-23 receptor antagonist; Sotyktu; deucravacitinib; plaque psoriasis; Phase 3 clinical trial; skin clearance; oral peptide; Bristol Myers Squibb

J&J’s Icotrokinra (JNJ-2113) Achieves Significant Success in Phase 3 Trials for Moderate to Severe Plaque Psoriasis

11 months ago talkbio0Tagged Clinical Trials, Dental Plaque, IL-23 receptor antagonist, JNJ-2113, Phase, Protagonist Therapeutics, Psoriasis

JNJ-2113, icotrokinra, IL-23 receptor antagonist, plaque psoriasis, Phase 3 clinical trials, Johnson & Johnson, Protagonist Therapeutics